News und Analysen
EQS-Adhoc: STRATEC POSTS PRELIMINARY RESULTS FOR FIRST HALF AND ADJUSTS GUIDANCE FOR 2023 FINANCIAL YEAR
EQS-Adhoc: STRATEC POSTS PRELIMINARY RESULTS FOR FIRST HALF AND ADJUSTS GUIDANCE FOR 2023 FINANCIAL YEAR
EQS-News: STRATEC COMPLETES ACQUISITION OF NATECH PLASTICS
EQS-News: STRATEC COMPLETES ACQUISITION OF NATECH PLASTICS
EQS-News: STRATEC SE: STRATEC FURTHER EXPANDS ITS PRESENCE IN USA BY ACQUIRING NATECH PLASTICS
EQS-News: STRATEC SE: STRATEC FURTHER EXPANDS ITS PRESENCE IN USA BY ACQUIRING NATECH PLASTICS
EQS-News: STRATEC’S ANNUAL GENERAL MEETING APPROVES FURTHER DIVIDEND INCREASE: DISTRIBUTION RISES TO € 0.97 PER SHARE
EQS-News: STRATEC’S ANNUAL GENERAL MEETING APPROVES FURTHER DIVIDEND INCREASE: DISTRIBUTION RISES TO € 0.97 PER SHARE
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE
EQS-News: STRATEC REPORTS FINAL FIGURES FOR 2022 FINANCIAL YEAR
EQS-News: STRATEC REPORTS FINAL FIGURES FOR 2022 FINANCIAL YEAR
EQS-Adhoc: STRATEC REPORTS PRELIMINARY RESULTS FOR 2022 FINANCIAL YEAR AND ISSUES FINANCIAL GUIDANCE FOR 2023
EQS-Adhoc: STRATEC REPORTS PRELIMINARY RESULTS FOR 2022 FINANCIAL YEAR AND ISSUES FINANCIAL GUIDANCE FOR 2023
EQS-News: STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
EQS-News: STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE
EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE
EQS-News: STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022
EQS-News: STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022
EQS-Adhoc: STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2022 AND ADJUSTS SALES GUIDANCE
EQS-Adhoc: STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2022 AND ADJUSTS SALES GUIDANCE
DGAP-News: STRATEC REPORTS RESULTS FOR FIRST HALF OF 2022 AND CONFIRMS FINANCIAL GUIDANCE
DGAP-News: STRATEC REPORTS RESULTS FOR FIRST HALF OF 2022 AND CONFIRMS FINANCIAL GUIDANCE
DGAP-Adhoc: STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST HALF OF 2022 AND CONFIRMS FINANCIAL GUIDANCE
DGAP-Adhoc: STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST HALF OF 2022 AND CONFIRMS FINANCIAL GUIDANCE
DGAP-News: STRATEC’S ANNUAL GENERAL MEETING APPROVES DIVIDEND INCREASE AND EXTENSION TO SUPERVISORY BOARD
DGAP-News: STRATEC’S ANNUAL GENERAL MEETING APPROVES DIVIDEND INCREASE AND EXTENSION TO SUPERVISORY BOARD
DGAP-News: STRATEC POSTS GOOD START TO YEAR AND FURTHER SALES GROWTH IN FIRST QUARTER OF 2022
DGAP-News: STRATEC POSTS GOOD START TO YEAR AND FURTHER SALES GROWTH IN FIRST QUARTER OF 2022
Eckert & Ziegler: Charttechnik deutet Kursexplosion an!
Ein explosives charttechnisches Setup finden Trader zurzeit bei der Aktie von Eckert & Ziegler (WKN: 565970) vor. Verhält sich die Aktie regelkonform, winkt hier ein Kurssprung!
So konnte die Aktie
Eckert & Ziegler unter Abgabedruck: Die Alternative?!
Die Aktie von Eckert & Ziegler (WKN: 565970) steht heute unter Abgabedruck, nachdem das deutsche Vorzeige-Medizintechnikunternehmen seine aktuellen Quartalszahlen vorgelegt hat. Denn diese fielen
EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
EQS-News: Eckert & Ziegler Completes Change of Legal Form to SE
EQS-News: Eckert & Ziegler Completes Change of Legal Form to SE
EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177